Managing Asthma in Pregnancy (MAP) Study

A double-blind randomised controlled trial of FENO guided asthma therapy and clinical guideline guided asthma therapy in pregnant women with asthma to reduce asthma exacerbations

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12607000561482

Acronym

The MAP Study

Enrollment

242

Registered

2007-11-01

Start date

2007-05-28

Completion date

2010-07-09

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study in pregnant women with asthma compares the guiding of asthma therapy by FENO level to asthma therapy guided by clinical guidelines on reducing asthma exacerbations during pregnancy

Interventions

Asthma therapy (inhaled corticosteroid and long-acting beta-agonist therapy) adjusted according to exhaled nitric oxide measurement (FENO) during the 2nd and 3rd trimester of pregnancy (approximately 6 months)

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

12-20 weeks gestation Doctor diagnosis of asthma Symptoms of asthma or taken treatment for asthma in the last 12 months

Exclusion criteria

Concomittent chronic medical illness, chronic lung disease other than asthma, drug or alcohol dependence, inability to attend study visits, inability to perform spirometry, >3 courses of oral corticoseroids (OCS) in past year, Hospital admission for an asthma exacerbation in the past 3 months, on regular oral prednisolone or theophylline

Outcome results